sulforaphane has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulforaphane (SFN) has been indicated for the prevention and suppression of tumorigenesis in solid tumors." | 5.38 | Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. ( Kuo, CC; Lee, CM; Lin, LC; Wang, LS; Wu, AT; Wu, CH; Yang, WC; Yeh, CT; Yen, GC, 2012) |
| "Sulforaphane (SFN) has been indicated for the prevention and suppression of tumorigenesis in solid tumors." | 1.38 | Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. ( Kuo, CC; Lee, CM; Lin, LC; Wang, LS; Wu, AT; Wu, CH; Yang, WC; Yeh, CT; Yen, GC, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, LC | 1 |
| Yeh, CT | 1 |
| Kuo, CC | 1 |
| Lee, CM | 1 |
| Yen, GC | 1 |
| Wang, LS | 1 |
| Wu, CH | 1 |
| Yang, WC | 1 |
| Wu, AT | 1 |
1 other study available for sulforaphane and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function.
Topics: ADP-ribosyl Cyclase 1; Anticarcinogenic Agents; Antigens, CD34; Antineoplastic Agents; Apoptosis; Be | 2012 |